AAPL   373.70 (+2.63%)
MSFT   209.95 (+1.79%)
AMZN   3,003.92 (+3.93%)
NVDA   392.78 (+2.16%)
CGC   16.73 (+1.70%)
BABA   239.14 (+6.95%)
GE   6.95 (+1.91%)
TSLA   1,322.03 (+9.38%)
AMD   53.01 (+1.28%)
T   30.36 (+0.93%)
DIS   113.44 (+1.12%)
BAC   23.56 (+1.16%)
NFLX   495.17 (+3.83%)
BA   182.68 (+1.03%)
AAPL   373.70 (+2.63%)
MSFT   209.95 (+1.79%)
AMZN   3,003.92 (+3.93%)
NVDA   392.78 (+2.16%)
CGC   16.73 (+1.70%)
BABA   239.14 (+6.95%)
GE   6.95 (+1.91%)
TSLA   1,322.03 (+9.38%)
AMD   53.01 (+1.28%)
T   30.36 (+0.93%)
DIS   113.44 (+1.12%)
BAC   23.56 (+1.16%)
NFLX   495.17 (+3.83%)
BA   182.68 (+1.03%)
AAPL   373.70 (+2.63%)
MSFT   209.95 (+1.79%)
AMZN   3,003.92 (+3.93%)
NVDA   392.78 (+2.16%)
CGC   16.73 (+1.70%)
BABA   239.14 (+6.95%)
GE   6.95 (+1.91%)
TSLA   1,322.03 (+9.38%)
AMD   53.01 (+1.28%)
T   30.36 (+0.93%)
DIS   113.44 (+1.12%)
BAC   23.56 (+1.16%)
NFLX   495.17 (+3.83%)
BA   182.68 (+1.03%)
AAPL   373.70 (+2.63%)
MSFT   209.95 (+1.79%)
AMZN   3,003.92 (+3.93%)
NVDA   392.78 (+2.16%)
CGC   16.73 (+1.70%)
BABA   239.14 (+6.95%)
GE   6.95 (+1.91%)
TSLA   1,322.03 (+9.38%)
AMD   53.01 (+1.28%)
T   30.36 (+0.93%)
DIS   113.44 (+1.12%)
BAC   23.56 (+1.16%)
NFLX   495.17 (+3.83%)
BA   182.68 (+1.03%)
Log in

NASDAQ:ALXNAlexion Pharmaceuticals Stock Price, Forecast & News

$113.41
+1.11 (+0.99 %)
(As of 07/6/2020 12:50 PM ET)
Add
Compare
Today's Range
$112.48
Now: $113.41
$113.86
50-Day Range
$100.92
MA: $111.26
$119.90
52-Week Range
$72.67
Now: $113.41
$134.84
Volume29,727 shs
Average Volume2.03 million shs
Market Capitalization$25.04 billion
P/E Ratio10.68
Dividend YieldN/A
Beta1.46
Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis. It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia; and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. In addition, the company conducts Phase III clinical trials for ALXN 1210 (IV) that is in Phase III clinical trials for the treatment of PNH and aHUS; ALXN1210 (Subcutaneous), which is in Phase I for PNH and aHUS; and Soliris (eculizumab) for the treatment of myasthenia gravis and neuromyelitis optica spectrum disorder. Further, it develops ALXN1840 (WTX101) that is in Phase III clinical trials for the treatment of Wilson disease; and ALXN1830 (SYNT001), which is in Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other healthcare providers in the United States, Europe, the Asia Pacific, and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc. to use drug-delivery technology in the development of subcutaneous formulations for its portfolio of products; collaboration with Dicerna Pharmaceuticals, Inc. to discover and develop RNAi therapies for complement-mediated diseases, as well as with Zealand Pharma A/S; strategic agreement with Caelum Biosciences, Inc. to advance the development of CAEL-101 for light chain (AL) amyloidosis; and partnership with Affibody AB. The company was founded in 1992 and is headquartered in Boston, Massachusetts.
Read More
Alexion Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.4Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 3.1 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.32 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:ALXN
CUSIP01535110
Phone475-230-2596

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$4.99 billion
Cash Flow$11.80 per share
Book Value$50.91 per share

Profitability

Net Income$2.40 billion

Miscellaneous

Employees3,082
Market Cap$25.04 billion
Next Earnings Date7/22/2020 (Estimated)
OptionableOptionable

Receive ALXN News and Ratings via Email

Sign-up to receive the latest news and ratings for ALXN and its competitors with MarketBeat's FREE daily newsletter.

Alexion Pharmaceuticals (NASDAQ:ALXN) Frequently Asked Questions

How has Alexion Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Alexion Pharmaceuticals' stock was trading at $83.77 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ALXN stock has increased by 35.4% and is now trading at $113.41. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Alexion Pharmaceuticals?

24 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alexion Pharmaceuticals in the last year. There are currently 1 sell rating, 6 hold ratings, 16 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Alexion Pharmaceuticals.

When is Alexion Pharmaceuticals' next earnings date?

Alexion Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, July 22nd 2020. View our earnings forecast for Alexion Pharmaceuticals.

How were Alexion Pharmaceuticals' earnings last quarter?

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) issued its quarterly earnings data on Wednesday, May, 6th. The biopharmaceutical company reported $3.22 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.71 by $0.51. The biopharmaceutical company had revenue of $1.44 billion for the quarter, compared to analyst estimates of $1.36 billion. Alexion Pharmaceuticals had a net margin of 44.83% and a return on equity of 21.96%. The business's revenue for the quarter was up 26.7% on a year-over-year basis. During the same quarter last year, the business posted $2.39 earnings per share. View Alexion Pharmaceuticals' earnings history.

What guidance has Alexion Pharmaceuticals issued on next quarter's earnings?

Alexion Pharmaceuticals issued an update on its FY20 earnings guidance on Wednesday, May, 6th. The company provided earnings per share (EPS) guidance of $10.45-$10.75 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $10.96. The company issued revenue guidance of $5.23-$5.33 billion, compared to the consensus revenue estimate of $5.51 billion.

What price target have analysts set for ALXN?

24 analysts have issued 1 year price targets for Alexion Pharmaceuticals' shares. Their forecasts range from $110.00 to $180.00. On average, they anticipate Alexion Pharmaceuticals' share price to reach $143.95 in the next twelve months. This suggests a possible upside of 26.9% from the stock's current price. View analysts' price targets for Alexion Pharmaceuticals.

Has Alexion Pharmaceuticals been receiving favorable news coverage?

Media stories about ALXN stock have trended negative recently, according to InfoTrie Sentiment Analysis. The research group ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Alexion Pharmaceuticals earned a media sentiment score of -2.1 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news about Alexion Pharmaceuticals.

Are investors shorting Alexion Pharmaceuticals?

Alexion Pharmaceuticals saw a decrease in short interest in June. As of June 15th, there was short interest totaling 4,500,000 shares, a decrease of 5.3% from the May 31st total of 4,750,000 shares. Based on an average trading volume of 2,620,000 shares, the short-interest ratio is presently 1.7 days. Approximately 2.1% of the shares of the stock are sold short. View Alexion Pharmaceuticals' Current Options Chain.

Who are some of Alexion Pharmaceuticals' key competitors?

What other stocks do shareholders of Alexion Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alexion Pharmaceuticals investors own include Alibaba Group (BABA), Gilead Sciences (GILD), NVIDIA (NVDA), Netflix (NFLX), Micron Technology (MU), Celgene (CELG), AbbVie (ABBV), Walt Disney (DIS), Visa (V) and Biogen (BIIB).

Who are Alexion Pharmaceuticals' key executives?

Alexion Pharmaceuticals' management team includes the following people:
  • Dr. Ludwig N. Hantson, CEO & Director (Age 56)
  • Mr. Paul J. Clancy, Exec. VP & CFO (Age 57)
  • Ms. Anne-Marie Law, Exec. VP and Chief Patient & Employee Experience Officer (Age 52)
  • Mr. Brian M. Goff, Exec. VP & Chief Commercial Officer (Age 50)
  • Dr. John J. Orloff, Exec. VP and Head of R&D (Age 62)

What is Alexion Pharmaceuticals' stock symbol?

Alexion Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALXN."

Who are Alexion Pharmaceuticals' major shareholders?

Alexion Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Fulton Bank N. A. (0.01%). Company insiders that own Alexion Pharmaceuticals stock include Aradhana Sarin, Bros Advisors Lp Baker, Daniel Bazarko, Indrani Lall Franchini, Ludwig Hantson and Paul J Clancy. View institutional ownership trends for Alexion Pharmaceuticals.

Which institutional investors are selling Alexion Pharmaceuticals stock?

ALXN stock was sold by a variety of institutional investors in the last quarter, including Fulton Bank N. A.. View insider buying and selling activity for Alexion Pharmaceuticals.

How do I buy shares of Alexion Pharmaceuticals?

Shares of ALXN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Alexion Pharmaceuticals' stock price today?

One share of ALXN stock can currently be purchased for approximately $113.41.

How big of a company is Alexion Pharmaceuticals?

Alexion Pharmaceuticals has a market capitalization of $25.04 billion and generates $4.99 billion in revenue each year. The biopharmaceutical company earns $2.40 billion in net income (profit) each year or $9.74 on an earnings per share basis. Alexion Pharmaceuticals employs 3,082 workers across the globe.

What is Alexion Pharmaceuticals' official website?

The official website for Alexion Pharmaceuticals is www.alexion.com.

How can I contact Alexion Pharmaceuticals?

Alexion Pharmaceuticals' mailing address is 121 SEAPORT BOULEVARD, BOSTON MA, 02210. The biopharmaceutical company can be reached via phone at 475-230-2596 or via email at [email protected]

This page was last updated on 7/6/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.